Project Funding

Funding for the RareConnect project comes from several types of sources such as patient organisations (AFM), public funds (EAHC) and pharmaceutical companies. All funding supports the project as a whole and plays an essential part in launching and sustaining all participating rare disease communities.

Written by RareConnect team, published 10 months ago.

AFM (French Association for Neuromuscular Disorders)

European Commission DG Health and Consumers
Alexion Pharmaceuticals
Celgene Corporation
Chiesi
DLA Piper

 

GSK

 

 

Novartis

 

 

Pfizer

 

 

Therakos

Medtronic Foundation

The material only reflects the views of the author, and funders cannot be held responsible for any use which may be made of the information contained herein.

Written by RareConnect team, published 10 months ago.

No comment for «Project Funding»

Expand all ]

No comment yet.

Leave a comment

You must be registered and signed in to leave a comment. Sign in now.